Matthew Sharpe, M.D.
NPI 1285775049 · Pulmonary Disease Physician · Kansas City, KS
Enrolled with Medicare as Practitioner - Pulmonary Disease · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1285775049
- Entity type
- Individual
- Primary specialty
- Pulmonary Disease PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Female
- Sole proprietor
- No
- License
- 04-29868 (KS)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
19 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
1,106 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Test to Measure Expiratory Airflow and Volume94010 | 211 | $8 |
| Test to Examine How Well the Lungs Exchange Gases94729 | 182 | $8 |
| Test to Determine Lung Volumes Using Sensors94726 | 151 | $11 |
| Subsequent Hospital Care With Moderate Levelof Medical Decision Making, If Using Time, at Least 50 Minutes99233 | 100 | $114 |
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 80 | $92 |
| Critical Care, First 30-74 Minutes99291 | 64 | $200 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 26 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Prednisone | 125 | 46 |
| Albuterol Sulfatebrand: Albuterol Sulfate Hfa | 110 | 39 |
| Fluticasone/Umeclidin/Vilanterbrand: Trelegy Ellipta | 88 | 20 |
| Azithromycin | 76 | 36 |
| Montelukast Sodium | 74 | 23 |
| Fluticasone/Vilanterolbrand: Breo Ellipta | 51 | — |
| Budesonide/Formoterol Fumarate |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$188,888 across 125 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2007-02-12
- Last updated
- 2025-09-11
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.